PREP and Alzheimer disease: Importantly, PreP was shown to degrade Aβ variants in vitro (Falkevall et al., 2006) and PreP activity is lower in the temporal lobes of AD patients and transgenic AD mice compared with controls, which may be further attributed to disease-related oxidative modifications (Alikhani et al., 2011b).